BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.
Aguiar, Innoviva's President and Chief Executive Officer and Eric
d'Esparbes, the Company's Senior Vice President and Chief Financial
Officer will participate in the 2017 Baird Global Healthcare Conference
at The InterContinental New York Barclay Hotel on Thursday, September 7,
from 12:50 pm - 1:20 pm ET.
The presentation will be available to interested parties live and for 90
days following the presentation using the following link: http://wsw.com/webcast/baird49/inva
or via the investor relations section of the Innoviva website at www.inva.com.
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva
and GSK. Under the agreement with GSK, Innoviva is eligible to receive
associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO®
ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest
in future payments made by GSK for earlier-stage programs partnered with
Theravance BioPharma, Inc., including the closed triple combination
therapy for Chronic Obstructive Pulmonary Disease (COPD). For more
information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170830006020/en/
Senior Vice President and Chief
Source: Innoviva, Inc.
News Provided by Acquire Media